|
The Science
Lead Compound
131I-CLR1404 is Cellectar's lead compound for cancer therapy, and it is currently in the pre-clinical stage. Cellectar will focus initially on therapeutic indications for CLR1404. The selection of CLR1404 as a viable diagnostic agent was based on early laboratory research on phospholipid ether analogs (PLEs) conducted at the University of Michigan in the lab of Dr. Ray Counsell. This early work was then expanded by Dr. Weichert and team at the University of Michigan and at the University of Wisconsin-Madison. Cellectar holds an exclusive license to related intellectual property from the University of Michigan.
Empirical evidence has shown that PLEs and their analogs (similar, synthetic compounds) become trapped in tumor cell membranes because the tumor cells cannot metabolize and eliminate them. Normal cells, however, appear to metabolize and clear these compounds.
Our scientists have based the development of their proprietary PLE analog compounds on extensive medicinal chemistry experimentation. Idophenyl phospholipid ether analogs are specifically designed so that the radioiodine affixed to each molecule is stable to in-vivo de-iodination. Extensive structure activity relationship studies with over 30 radioiodinated PLE analogs have shown that any chemical modification of the phosphocholine moiety or shortening the chain length of the Iodophenylalkyl moiety to less than 8 methylenes resulted in little or no malignant tumor uptake. Results of these experiments are detailed in a recent publication in the Journal of Medicinal Chemistry: Pinchuck, etal 49:2155-2165 (2006).
Cellectar produces its PLE analog small molecule compounds by chemical organic synthesis.
In pre-clinical studies, CLR1404 has selectively accumulated in 100% of the 42 tumor types tested. Click here for the full list of xenograft and spontaneous human and rodent tumor models tested. Previous investigator-sponsored clinical trials have already shown that CLR1404 can be safely administered to humans and that CLR1404 accumulates in human NSCLC tumors, confirming preclinical results.
Gallery of Images
 View remarkable images of CLR1404's tumor selectivity and retention.
Radioisotope Selection
View information regarding radioisotope selection.
Cancer Treatment
View information regarding cancer treatment.
Cancer Diagnosis
View for information regarding cancer diagnosis.
Tumor Types Tested with CLR1404
View the current list of tumor types tested.
Download current list of tumor types tested ( PDF).
| 
